No Data
Bide Pharmaceutical's net profit in 2024 increased by 7.17% year-on-year, with the Overseas market becoming the growth engine.
In 2024, Bid achieved an annual revenue of 1.102 billion yuan, a year-on-year increase of 0.93%; the net income attributable to the parent company's shareholders was 0.117 billion yuan, a year-on-year increase of 7.17%; the company stated it will continue to optimize the product structure, deepen its global layout, and increase R&D investment to respond to changes in the industry technology.
With A 27% Price Drop For Bide Pharmatech Co., Ltd. (SHSE:688073) You'll Still Get What You Pay For
Bide Pharmaceuticals: Report for the first quarter of 2025
Bide Pharmatech: 2024 Annual Report
Summary of the 2024 Annual Report.
First Quarter Report of 2025.
Are Bide Pharmatech Co., Ltd.'s (SHSE:688073) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?